May 21 | News
Auxilium Pharmaceuticals, Inc. and GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc, announced today that they have entered into an agreement for the co-promotion of Testim 1% (testosterone gel), which is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of testosterone.
|
May 19 | News
GlaxoSmithKline plc (“GSK”) (LSE:GSK) and Theravance, Inc. (“Theravance”) (NASDAQ: THRX) announced today that following approval by Theravance, Inc.‟s stockholders at their Annual Meeting held on 15 May 2012, and expiration of applicable waiting periods under the US Hart-Scott-Rodino...
|
May 19 | News
GlaxoSmithKline plc (LSE: GSK) today commented on Human Genome Sciences (NASDAQ: HGSI) Board of Directors’ decision to recommend against GSK’s tender offer to acquire all of the outstanding shares of HGS for US$13.00 per share in cash. The offer represents a premium of 81 percent to HGS’s...
|
May 19 | News
For the first time in its 15 year history the judges of the GlaxoSmithKline (GSK) IMPACT Awards could not choose one overall winner for the awards so instead awarded two prizes.
|
May 18 | News
LONDON (AP) — GlaxoSmithKline says it will persist with its bid to take over U.S. company Human Genome Sciences despite the target's new 'poison pill' defense.
|
May 17 | News
ROCKVILLE, Md. (AP) — Human Genome Sciences says its board has adopted a "poison pill" shareholder rights plan to ward off unsolicited takeover bids for the biotech drugmaker.
|
May 14 | News
GSK announced that it will not participate in Human Genome Sciences strategic alternatives review process and will instead commence a tender offer this week to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.
|
May 14 | News
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
|
May 14 | News
Stiefel, a GSK (NYSE:GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%.
|
May 5 | News
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board
|